INOVIQ LTD — Capital/Financing Update 2018

Mar 21, 2018

==> picture [155 x 46] intentionally omitted <==

CAPITAL RAISING

Perth, Australia, 22 March 2018: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), a biotechnology company developing non-invasive cancer diagnostics, is pleased to announce that it has received binding commitments for a share placement to raise $1,300,000 (before expenses) by the issue of 86,666,666 shares to sophisticated and professional investors at an issue price of $0.015 cents per share (Placement). The placement was made to high net worth and institutional clients of Taurus Capital Group.

The Placement will be made under the Company’s existing placement capacities available under ASX Listing Rule 7.1. It is anticipated that settlement of the Placement will occur by 26 March 2018 with the Placement shares to be issued shortly after.

All new shares issued under the Placement will rank equally in all respects with the existing fully paid ordinary shares of the Company.

Funds raised from the Placement will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in early development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see www.bard1.com.

BARD1 Life Sciences Limited (ABN 58 009 070 384) Headquarters | Harry Perkins Institute, L2/QQ Block, 6 Verdun St, Nedlands WA 6009, Australia Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com